Cancer Research Technology (CRT), specialist in oncology-focused development and commercialisation, announces the recruitment of Prof Lloyd Kelland as head of biology at its development laboratories
Clive Stanway, CRT's director of technology development, stated "We are delighted to have recruited Prof Kelland to CRT.
"Our biotherapeutic and drug discovery programmes and the organisation as a whole will benefit greatly from his experience and expertise".
Kelland will join CRT from Antisoma, where he is currently the head of research.
Prior to Antisoma, he was a principal investigator at the Cancer Research UK Centre for Cancer Therapeutics at the prestigious Institute of Cancer Research.
In these positions Kelland has been instrumental in the development of a number of anti-cancer agents currently in advanced clinical development and has published in excess of 150 papers in the field of preclinical cancer drug development.
Kelland's experience of both academic and commercial-based drug development will be invaluable for CRT, an organisation that through collaboration builds on academic research to create attractive commercial partnerships.
